I am sharing some preliminary work that led to the intervention in this clinical trial. I look forward to sharing the results on Sunday.
www-ovid-com.proxy.lib.umich.eduwww-ahajournals-org.proxy.lib.umich.eduWhat happened
ENGAGE-HF digital intervention improves 90-day guideline-directed medication score by ~10 points over usual care.
I am sharing some preliminary work that led to the intervention in this clinical trial. I look forward to sharing the results on Sunday.
www-ovid-com.proxy.lib.umich.eduwww-ahajournals-org.proxy.lib.umich.edu📌Sim Pub w/ #ScientificSessions26: Can digital health accelerate GDMT optimization? Randomized ENGAGE-HF trial shows improved #GDMT optimization at 90 days: 83.7% vs 74.0% (P=0.010) Greater uptake of MRAs & SGLT2 inhibitors A promising approach to post-discharge HF care
t.coDigital HF Medication RCTAnswers are grounded in this paper and cite their sources.
Why the trial, tables, limitations, PICO, abstract, media & sources
Although guideline-directed medical therapy (GDMT) reduces mortality and hospitalizations in patients with heart failure with reduced and mildly reduced ejection fraction, its real-world implementation remains suboptimal. This trial was conducted to evaluate whether a digital health intervention combining a patient-facing mobile app and a clinician dashboard could improve GDMT titration following hospital discharge.
Does the ENGAGE-HF digital health intervention improve guideline-directed medical therapy optimization at 90 days compared with usual care in recently hospitalized patients with heart failure and LVEF <50%?
Does the ENGAGE-HF digital health intervention improve guideline-directed medical therapy optimization at 90 days compared with usual care in recently hospitalized patients with heart failure and LVEF <50%?
A digital health intervention integrating remote monitoring, a patient-facing app, and a clinician dashboard significantly improves post-discharge GDMT optimization at 90 days in patients with heart failure and LVEF <50%.
Background: Despite clear evidence that guideline-directed medical therapy (GDMT) significantly reduces mortality and hospitalizations in patients with heart failure (HF) with reduced and mildly reduced ejection fraction, real-world implementation remains suboptimal. Digital health interventions may promote GDMT titration after hospital discharge. Methods: The ENGAGE-HF trial was a multicenter, two-arm, open-label, randomized controlled trial across three academic centers, funded by the AHA Strategically Focused Research Network (SFRN) for Health Technology and Innovation. Patients recently hospitalized with HF, with or without a primary hospital diagnosis of HF, and LVEF <50% receiving suboptimal GDMT were randomized 1:1 to either the ENGAGE-HF app or usual care for 90 days. The ENGAGE-HF intervention consisted of a patient-facing mobile app and a clinician dashboard overseen by study coordinators. The primary outcome was the Medication Optimization Score (MOS, scale 0-100%) at 90 days. Secondary outcomes were individual GDMT therapies and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 90 days. Results: A total of 134 participants were randomized. At 90 days, the adjusted MOS was significantly higher in the ENGAGE-HF group compared to the control group (83.7% vs. 74.0%, p = 0.010). Results remained consistent across multiple sensitivity analyses. Overall prescribing prevalence increased more in the ENGAGE-HF group for MRAs (+15.9 vs. +2.5 percentage points) and SGLT2 inhibitors (+10.9 vs. +2.5 percentage points). Furthermore, the ENGAGE-HF group demonstrated greater increases in achieving target doses for ARNI (+18.8% vs. +6.3%) and beta-blockers (+8.5% vs. +0.6%). KCCQ-23 CSS at 90 days was 75.2 (SE 2.6) in the intervention group versus 72.2 (SE 2.6) in the control group (between-group p = 0.40). Conclusions: ENGAGE-HF, a digital health intervention that integrates remote monitoring, patient engagement, and clinical decision support, significantly improved GDMT optimization at 90 days compared with usual care among patients with HF. Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT06750549
Dorsch et al. (2026) conducted an RCT in Heart failure with LVEF <50% (n=134). ENGAGE-HF digital health intervention (patient-facing mobile app and clinician dashboard overseen by study coordinators) vs. Usual care was evaluated on Medication Optimization Score (MOS, scale 0-100%) at 90 days (p=0.010). The ENGAGE-HF digital health intervention significantly increased the 90-day Medication Optimization Score compared with usual care (83.7% vs. 74.0%, p = 0.010).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: